Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab dose-randomized phase II induction study in relapsed adult acute lymphoblastic leukemia
ISRCTN86445183Phase 2Completed
- Sponsor
- HOVON
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alemtuzumab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by HOVON. Primary endpoints: Complete remission on induction cycle I and Severe toxicity on induction cycle I. Started May 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN86445183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86445183.